Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Myszkowski sold 16,104 shares of the company's stock on January 5, 2024, according to a SEC Filing. The transaction was executed at an average price of $35.27 per share, resulting in a total value of $567,948.08.
Arrowhead Pharmaceuticals Inc is a biopharmaceutical company that develops medicines to treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. The company's products in development aim to treat diseases with a genetic basis, typically involving a single gene that produces a harmful protein.
Over the past year, the insider has sold a total of 31,104 shares and has not made any purchases. The recent sale by the CFO is part of a series of insider transactions at Arrowhead Pharmaceuticals Inc. In the past year, there have been 19 insider sells and no insider buys.
On the valuation front, Arrowhead Pharmaceuticals Inc's shares were trading at $35.27 on the day of the insider's sale, giving the company a market capitalization of $4.864 billion. The stock's price-to-GF-Value ratio stands at 0.86, indicating that it is Fairly Valued when compared to the GF Value of $41.22.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also includes an adjustment factor based on the company's historical returns and growth, as well as future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
